Q1 EPS Forecast for Merit Medical Systems Lowered by Analyst

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Zacks Research dropped their Q1 2025 earnings estimates for Merit Medical Systems in a report released on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings per share of $0.76 for the quarter, down from their prior estimate of $0.81. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.37 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q2 2025 earnings at $0.96 EPS, Q4 2025 earnings at $1.02 EPS, Q1 2026 earnings at $0.74 EPS, Q2 2026 earnings at $1.08 EPS, Q3 2026 earnings at $1.10 EPS, Q4 2026 earnings at $1.15 EPS and FY2027 earnings at $4.34 EPS.

Several other research analysts have also recently issued reports on the company. Canaccord Genuity Group reduced their price objective on Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Barrington Research decreased their price objective on shares of Merit Medical Systems from $115.00 to $111.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. Piper Sandler reaffirmed an “overweight” rating and issued a $116.00 price objective (up from $114.00) on shares of Merit Medical Systems in a report on Wednesday, January 29th. Raymond James raised their target price on shares of Merit Medical Systems from $105.00 to $110.00 and gave the stock an “outperform” rating in a report on Tuesday, December 31st. Finally, Needham & Company LLC lowered their price target on shares of Merit Medical Systems from $122.00 to $116.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.78.

Merit Medical Systems Stock Performance

Shares of MMSI stock opened at $101.46 on Thursday. The business has a fifty day moving average of $103.76 and a 200 day moving average of $100.71. Merit Medical Systems has a 1 year low of $70.70 and a 1 year high of $111.45. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.36 and a quick ratio of 3.82. The firm has a market capitalization of $5.97 billion, a price-to-earnings ratio of 49.74, a price-to-earnings-growth ratio of 2.34 and a beta of 0.91.

Insider Activity at Merit Medical Systems

In related news, insider Brian G. Lloyd sold 25,000 shares of Merit Medical Systems stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $99.50, for a total value of $2,487,500.00. Following the completion of the sale, the insider now owns 38,993 shares in the company, valued at approximately $3,879,803.50. This trade represents a 39.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Stephen C. Evans sold 5,000 shares of Merit Medical Systems stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $105.31, for a total value of $526,550.00. Following the completion of the sale, the director now directly owns 4,657 shares of the company’s stock, valued at $490,428.67. The trade was a 51.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 109,132 shares of company stock worth $11,139,521. Insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Merit Medical Systems

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MMSI. Barclays PLC boosted its holdings in Merit Medical Systems by 305.4% in the third quarter. Barclays PLC now owns 112,727 shares of the medical instruments supplier’s stock valued at $11,142,000 after purchasing an additional 84,923 shares during the period. EULAV Asset Management raised its position in Merit Medical Systems by 400.0% in the 4th quarter. EULAV Asset Management now owns 115,000 shares of the medical instruments supplier’s stock valued at $11,123,000 after purchasing an additional 92,000 shares in the last quarter. Fisher Asset Management LLC boosted its stake in shares of Merit Medical Systems by 3.2% in the 3rd quarter. Fisher Asset Management LLC now owns 221,690 shares of the medical instruments supplier’s stock valued at $21,910,000 after buying an additional 6,837 shares during the period. JPMorgan Chase & Co. grew its position in shares of Merit Medical Systems by 85.6% during the third quarter. JPMorgan Chase & Co. now owns 575,946 shares of the medical instruments supplier’s stock worth $56,921,000 after buying an additional 265,648 shares in the last quarter. Finally, AMI Asset Management Corp increased its stake in shares of Merit Medical Systems by 28.7% during the fourth quarter. AMI Asset Management Corp now owns 33,041 shares of the medical instruments supplier’s stock worth $3,196,000 after buying an additional 7,367 shares during the period. Hedge funds and other institutional investors own 99.66% of the company’s stock.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.